NeuroMetrix (NASDAQ:NURO) Now Covered by StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of NeuroMetrix (NASDAQ:NURO) in a research note issued to investors on Thursday. The firm set a “sell” rating on the medical device company’s stock.

NeuroMetrix Trading Down 1.5 %

Shares of NASDAQ NURO opened at $4.51 on Thursday. The stock has a market cap of $9.26 million, a price-to-earnings ratio of -0.98 and a beta of 2.15. NeuroMetrix has a 52 week low of $2.66 and a 52 week high of $4.73. The company’s 50-day moving average price is $4.30 and its 200 day moving average price is $4.12.

Institutional Investors Weigh In On NeuroMetrix

An institutional investor recently bought a new position in NeuroMetrix stock. Renaissance Technologies LLC acquired a new stake in NeuroMetrix, Inc. (NASDAQ:NURO) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 11,560 shares of the medical device company’s stock, valued at approximately $46,000. Renaissance Technologies LLC owned about 0.57% of NeuroMetrix at the end of the most recent quarter. 19.40% of the stock is owned by institutional investors.

NeuroMetrix Company Profile

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.